"State laws cannot permit what federal law prohibits." If U.S. States can license storefronts to sell Federally-banned cannabis for recreational use without any sort of prescription, what's to prevent them from doing the same with peptides (assuming in-state API factories)?
And to go off on a tangent, a friend's best guess about what "feinereich" is up to is that they're doing venture-capital due diligence with the goal of acquiring or modeling high-performing grey vendors in preparation for the sort of changes (503C and beyond, as speculated in the article) that not only might be coming up, but that they'd lobby for. This would help explain their emphasis on domestic, single-vial vendors and their use of domestic laboratories, as well as the dollar amounts that seem incomprehensible to us non-VC plebeians.